Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. The CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. It also offers the TomoTherapy System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. The company markets its products in the United States directly, as well as through a sales agent and group purchasing organizations; and directly and through distributors and sales agents in Europe, Japan and other countries of Asia, South America, and internationally to hospitals and stand-alone treatment facilities. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone408-716-4600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$404.90 million
Profitability
Miscellaneous
Employees998
OptionableOptionable
Accuray (NASDAQ:ARAY) Frequently Asked Questions
What is Accuray's stock symbol?
Accuray trades on the NASDAQ under the ticker symbol "ARAY."
How were Accuray's earnings last quarter?
Accuray Incorporated (NASDAQ:ARAY) announced its earnings results on Tuesday, January, 22nd. The medical equipment provider reported ($0.05) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.08) by $0.03. The medical equipment provider had revenue of $102.32 million for the quarter, compared to analysts' expectations of $104.01 million. Accuray had a negative net margin of 5.79% and a negative return on equity of 42.24%. During the same period last year, the firm earned ($0.06) earnings per share. View Accuray's Earnings History.
When is Accuray's next earnings date?
What guidance has Accuray issued on next quarter's earnings?
Accuray issued an update on its FY 2019 earnings guidance on Tuesday, January, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $415-425 million, compared to the consensus revenue estimate of $420.67 million.
What price target have analysts set for ARAY?
4 equities research analysts have issued 1-year target prices for Accuray's shares. Their forecasts range from $3.90 to $6.00. On average, they expect Accuray's share price to reach $5.30 in the next twelve months. This suggests a possible upside of 20.5% from the stock's current price. View Analyst Price Targets for Accuray.
What is the consensus analysts' recommendation for Accuray?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Accuray.
What are Wall Street analysts saying about Accuray stock?
Here are some recent quotes from research analysts about Accuray stock:
- 1. According to Zacks Investment Research, "Accuray continues to gain from its flagship Radixact platform, which garnered sizeable orders in recent times and also drove the company’s TomoTherapy platform. A regulatory approval for Radixact X9 system in India buoys optimism. Gross orders rose in the United States and EMEA in recent times. Accuray’s service revenues also improved year over year lately. Significant expansion in the company’s gross margin is another positive. Accuray has kept its 2019 guidance intact. However, decline in APAC region orders owing to China issues, long sales and implementation cycle of the CyberKnife and TomoTherapy systems raise concern. Unfavorable product mix, sluggish macroeconomic conditions and pricing issues add to the apprehensions. Reflective of these, the stock has underperformed the industry over the past six months." (1/2/2019)
- 2. BTIG Research analysts commented, "While we were out sick, Accuray posted a ~$6M revenue beat but missed gross order expectations. Although the company fell short of its guided 5% y/y growth in gross orders for FY18, we liked the sales step up, strong revenue guidance for FY19, and the increasing funnel of anticipated multi- system orders. The company’s decision to move away from annual gross order guidance may bother some but is probably the correct move given mgmt’s inability to consistently accurately predict this. Pinning down an order growth rate is likely to become more challenging, as we expect more multi-system orders to add timing unpredictability and more lumpiness to quarterly numbers. Overall, while it may be tougher – at least near term – to get visibility into quarterly orders, we see larger multi-unit bookings as a win for ARAY." (8/22/2018)
Has Accuray been receiving favorable news coverage?
News stories about ARAY stock have been trending negative this week, InfoTrie reports. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Accuray earned a daily sentiment score of -2.1 on InfoTrie's scale. They also assigned media coverage about the medical equipment provider a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the company's share price in the next several days.
Who are some of Accuray's key competitors?
Some companies that are related to Accuray include Nevro (NVRO), AtriCure (ATRC), K2M Group (KTWO), Luminex (LMNX), Tactile Systems Technology (TCMD), Cryolife (CRY), Cardiovascular Systems (CSII), Orthofix Medical (OFIX), Intersect ENT (XENT), AngioDynamics (ANGO), Cerus (CERS), OraSure Technologies (OSUR), SurModics (SRDX), SI-Bone (SIBN) and Anika Therapeutics (ANIK).
Who are Accuray's key executives?
Accuray's management team includes the folowing people:
- Mr. Joshua H. Levine, Pres, CEO & Director (Age 61)
- Mr. Andrew Kirkpatrick, Sr. VP & COO (Age 56)
- Mr. Lionel Hadjadjeba, Sr. VP & Chief Customer Experience Officer (Age 60)
- Mr. Shigeyuki Hamamatsu, Sr. VP & CFO (Age 46)
- Mr. Patrick R. Spine, Sr. VP & Chief Admin. Officer
Who are Accuray's major shareholders?
Accuray's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.60%). Company insiders that own Accuray stock include Alaleh Nouri, Andrew J Kirkpatrick, Jesse Chew, Joshua Levine, Kelly Londy, Kevin Waters and Shigeyuki Hamamatsu. View Institutional Ownership Trends for Accuray.
Which major investors are buying Accuray stock?
How do I buy shares of Accuray?
Shares of ARAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Accuray's stock price today?
One share of ARAY stock can currently be purchased for approximately $4.40.
How big of a company is Accuray?
Accuray has a market capitalization of $381.30 million and generates $404.90 million in revenue each year. The medical equipment provider earns $-23,890,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis. Accuray employs 998 workers across the globe.
What is Accuray's official website?
How can I contact Accuray?
Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider can be reached via phone at 408-716-4600 or via email at [email protected]
MarketBeat Community Rating for Accuray (NASDAQ ARAY)
MarketBeat's community ratings are surveys of what our community members think about Accuray and other stocks. Vote "Outperform" if you believe ARAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
